[
    {
        "headline": "Solventum First Quarter 2025 Earnings: Beats Expectations",
        "text": "Solventum ( NYSE:SOLV ) First Quarter 2025 Results Key Financial Results Revenue: US$2.07b (up 2.7% from 1Q 2024). Net..."
    },
    {
        "headline": "Solventum to Participate in the 2025 BofA Securities Health Care Conference",
        "text": "Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV."
    },
    {
        "headline": "Solventum Reports First Quarter 2025 Financial Results",
        "text": "Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2025."
    },
    {
        "headline": "Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025",
        "text": "Solventum (NYSE: SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast."
    },
    {
        "headline": "Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations",
        "text": "Solventum (NYSE: SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays and more. This research and development (R&D) and commercialization agreement is focused on developing and bringing to market high-quality, durable and permanent same-day restorations – with the quality patients and dent"
    },
    {
        "headline": "Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day",
        "text": "Solventum (NYSE: SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long-range plan (LRP) to drive growth and value creation."
    },
    {
        "headline": "Alger Russell Innovation Index Updates for First Quarter 2025",
        "text": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, March 21, 2025, the Index will be rebalanced, and the following changes will be effective."
    },
    {
        "headline": "Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance",
        "text": "Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation."
    },
    {
        "headline": "Solventum forecasts annual profit above estimates on strong surgical product sales",
        "text": "Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. The company's performance has come under scrutiny from activist investor Nelson Peltz."
    },
    {
        "headline": "Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance",
        "text": "Solventum (NYSE: SOLV) today reported financial results for the fourth quarter ended December 31, 2024."
    },
    {
        "headline": "Nelson Peltz’s Trian Pushes Solventum to Further Simplify Business",
        "text": "Activist investor Trian Fund Management is pushing Solventum to separate more of its businesses after the company’s $4.1 billion deal to sell its filtration unit, according to people familiar with the matter. Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Trian believes the company should separate its dental products and software businesses and focus more on its medical and surgical unit, the people said."
    },
    {
        "headline": "Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City",
        "text": "Solventum (NYSE: SOLV) will host an investor day on Thursday, March 20, 2025, beginning at approximately 1:00 p.m. Eastern Standard Time. The event will be held in New York City and simultaneously webcast online."
    },
    {
        "headline": "Healthcare sector leading markets in 2025: What to know",
        "text": "Investors have been turning to the healthcare sector (XLV) as they search for safe haven investments amid recent market turbulence. Market Domination anchor Julie Hyman details how the industry has been outperforming the broader market (^DJI, ^IXIC, ^GSPC), noting some of the standouts in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination&nbsp;here. This post was written by Luke Carberry Mogan."
    },
    {
        "headline": "Trian Comments on Solventum’s Sale of its Purification & Filtration Business",
        "text": "NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on Solventum’s recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following statement: “Trian commends Solventum on the announced sale of its Purification & Filtratio"
    },
    {
        "headline": "Thermo Fisher Strikes Deal for Solventum’s Filtration Unit",
        "text": "Thermo Fisher Scientific said Tuesday it is buying Solventum’s purification and filtration business, confirming an earlier report by The Wall Street Journal. Thermo Fisher said it is paying about $4.1 billion in cash for the business. The Journal reported in October that Solventum, the healthcare company spun off from 3M last year, had retained bankers to explore a sale of its purification and filtration unit."
    },
    {
        "headline": "Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B",
        "text": "Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") for $4.1 billion. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing condi"
    },
    {
        "headline": "Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors",
        "text": "BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Amp"
    },
    {
        "headline": "Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging",
        "text": "Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time."
    },
    {
        "headline": "Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025",
        "text": "Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast."
    },
    {
        "headline": "Solventum Corporation (NYSE:SOLV) is largely controlled by institutional shareholders who own 63% of the company",
        "text": "Key Insights Given the large stake in the stock by institutions, Solventum's stock price might be vulnerable to their..."
    },
    {
        "headline": "Solventum First Quarter 2025 Earnings: Beats Expectations",
        "text": "Solventum ( NYSE:SOLV ) First Quarter 2025 Results Key Financial Results Revenue: US$2.07b (up 2.7% from 1Q 2024). Net..."
    },
    {
        "headline": "Solventum to Participate in the 2025 BofA Securities Health Care Conference",
        "text": "Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV."
    },
    {
        "headline": "Solventum Reports First Quarter 2025 Financial Results",
        "text": "Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2025."
    },
    {
        "headline": "Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025",
        "text": "Solventum (NYSE: SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast."
    },
    {
        "headline": "Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations",
        "text": "Solventum (NYSE: SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays and more. This research and development (R&D) and commercialization agreement is focused on developing and bringing to market high-quality, durable and permanent same-day restorations – with the quality patients and dent"
    },
    {
        "headline": "Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day",
        "text": "Solventum (NYSE: SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long-range plan (LRP) to drive growth and value creation."
    },
    {
        "headline": "Alger Russell Innovation Index Updates for First Quarter 2025",
        "text": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, March 21, 2025, the Index will be rebalanced, and the following changes will be effective."
    },
    {
        "headline": "Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance",
        "text": "Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation."
    },
    {
        "headline": "Solventum forecasts annual profit above estimates on strong surgical product sales",
        "text": "Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. The company's performance has come under scrutiny from activist investor Nelson Peltz."
    },
    {
        "headline": "Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance",
        "text": "Solventum (NYSE: SOLV) today reported financial results for the fourth quarter ended December 31, 2024."
    },
    {
        "headline": "Nelson Peltz’s Trian Pushes Solventum to Further Simplify Business",
        "text": "Activist investor Trian Fund Management is pushing Solventum to separate more of its businesses after the company’s $4.1 billion deal to sell its filtration unit, according to people familiar with the matter. Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Trian believes the company should separate its dental products and software businesses and focus more on its medical and surgical unit, the people said."
    },
    {
        "headline": "Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City",
        "text": "Solventum (NYSE: SOLV) will host an investor day on Thursday, March 20, 2025, beginning at approximately 1:00 p.m. Eastern Standard Time. The event will be held in New York City and simultaneously webcast online."
    },
    {
        "headline": "Healthcare sector leading markets in 2025: What to know",
        "text": "Investors have been turning to the healthcare sector (XLV) as they search for safe haven investments amid recent market turbulence. Market Domination anchor Julie Hyman details how the industry has been outperforming the broader market (^DJI, ^IXIC, ^GSPC), noting some of the standouts in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination&nbsp;here. This post was written by Luke Carberry Mogan."
    },
    {
        "headline": "Trian Comments on Solventum’s Sale of its Purification & Filtration Business",
        "text": "NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on Solventum’s recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following statement: “Trian commends Solventum on the announced sale of its Purification & Filtratio"
    },
    {
        "headline": "Thermo Fisher Strikes Deal for Solventum’s Filtration Unit",
        "text": "Thermo Fisher Scientific said Tuesday it is buying Solventum’s purification and filtration business, confirming an earlier report by The Wall Street Journal. Thermo Fisher said it is paying about $4.1 billion in cash for the business. The Journal reported in October that Solventum, the healthcare company spun off from 3M last year, had retained bankers to explore a sale of its purification and filtration unit."
    },
    {
        "headline": "Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B",
        "text": "Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE: TMO) (\"Thermo Fisher\") for $4.1 billion. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing condi"
    },
    {
        "headline": "Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors",
        "text": "BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Amp"
    },
    {
        "headline": "Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging",
        "text": "Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time."
    },
    {
        "headline": "Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025",
        "text": "Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast."
    },
    {
        "headline": "Solventum Corporation (NYSE:SOLV) is largely controlled by institutional shareholders who own 63% of the company",
        "text": "Key Insights Given the large stake in the stock by institutions, Solventum's stock price might be vulnerable to their..."
    },
    {
        "headline": "Trian Issues Open Letter to Solventum Shareholders",
        "text": "Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company’s Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio Actions and Prudent Capital Allocation NEW YORK, Jan. 08, 2025 (GLOBE NEWS"
    },
    {
        "headline": "The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing",
        "text": "The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Mily as Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a comprehensive approach to c"
    },
    {
        "headline": "Is Solventum Corporation (NYSE:SOLV) Trading At A 31% Discount?",
        "text": "Key Insights Solventum's estimated fair value is US$95.40 based on 2 Stage Free Cash Flow to Equity Solventum's..."
    },
    {
        "headline": "Honeywell Mulls A Move That May Herald Aerospace Megamerger",
        "text": "A standalone Honeywell aerospace business could be worth up to $120 billion. Honeywell stock rose on Monday."
    },
    {
        "headline": "Should You Be Excited About Solventum Corporation's (NYSE:SOLV) 23% Return On Equity?",
        "text": "One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will..."
    },
    {
        "headline": "Solventum to Participate in the Piper Sandler Healthcare Conference",
        "text": "Solventum (NYSE: SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY."
    },
    {
        "headline": "Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment",
        "text": "This month, Solventum (NYSE: SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creating durable, accurately shaped, stain resistant attachments."
    },
    {
        "headline": "Solventum price target raised to $73 from $60 at Morgan Stanley",
        "text": "Morgan Stanley raised the firm’s price target on Solventum (SOLV) to $73 from $60 and keeps an Equal Weight rating on the shares. Solventum, which “had a clean 3Q print,” seems to be navigating a difficult MedTech backdrop relatively well, especially within the core MedSurg business, the analyst tells investors in a post-earnings note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>"
    },
    {
        "headline": "Solventum Third Quarter 2024 Earnings: Beats Expectations",
        "text": "Solventum ( NYSE:SOLV ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.08b (flat on 3Q 2023). Net..."
    },
    {
        "headline": "Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance",
        "text": "Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024."
    },
    {
        "headline": "The Second-Best Dow Jones Stock Of 2024 Whipsawed After Earnings Beat",
        "text": "3M, Dow Jones Industrial Average component, flirted with a breakout on Tuesday morning after reporting better than expected earnings."
    },
    {
        "headline": "Solventum Stock Earns 81 RS Rating",
        "text": "Solventum stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 78 to 81. The healthcare solutions stock debut Mar. 26. IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score."
    },
    {
        "headline": "Solventum commits to 100% renewable electricity by 2030",
        "text": "Solventum, formerly 3M Health Care, pledges to use 100% renewable electricity across its worldwide operations by 2030. Since 2021, Solventum has transitioned ten manufacturing sites across the United States, Canada, Germany, Poland and France to renewable electricity, accounting for 48% of the company’s total electricity consumption. Solventum is on track to increase this amount to 80% by 2025, a significant step towards meeting the 2030 target. The transition to 100% renewable electricity is an"
    },
    {
        "headline": "Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024",
        "text": "Solventum (NYSE: SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business."
    },
    {
        "headline": "Solventum Announces Commitment to 100% Renewable Electricity by 2030",
        "text": "Solventum (NYSE: SOLV), formerly 3M Health Care, today pledges to use 100% renewable electricity across its worldwide operations by 2030. This move highlights Solventum's commitment to sustainability and the critical role of the healthcare industry in addressing climate change. It also demonstrates how the company is integrating sustainable practices in its facilities and innovating solutions for customers."
    }
]